Unizink

Quick links to important sections

Unizink

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Unizink

Property Description
Active ingredient Zinc Aspartate
Form Tablets, Capsules, IV Solution
Pharmacological class Essential Trace Element Supplement
General Purpose Zinc Substitution/Deficiency Correction
Origin Synthetic, Organic Complex

Unizink: Definition and Pharmacological Classification

Unizink is defined as an essential trace element supplement, classified within the high-level Pharmacological class of zinc preparations. Its primary purpose is zinc substitution, serving to address zinc deficiency states that cannot be corrected solely through diet, a strategy for managing this micronutrient imbalance. Zinc is an indispensable trace element, the second most common after iron in the human body, necessary for vast biological functions. As a Monopreparation, Unizink is singularly focused on replenishing the Zinc ion to support the body in sustaining normal metabolic functions.

Composition and Origin: The Role of Zinc Aspartate

The active ingredient in this preparation is Zinc Aspartate, chemically defined as Zinc bis(hydrogen-DL-aspartate). This compound is a synthetic structure, an organic zinc complex, formed by chelating the Zinc ion with the amino acid derivative L-Aspartic Acid. This specific chelated structure is designed for high bioavailability and enhanced gastric tolerance when compared to simple inorganic zinc salts. This means the formulation is developed to ensure efficient absorption and suitability for oral supplementation.

Available Forms: Oral and Systemic Preparations

Unizink is presented in several distinct pharmaceutical preparations to accommodate varying requirements for zinc substitution. The preparation is available for the oral route of administration as Film-coated tablets and Enteric-coated tablets. The enteric-coating represents a formulation feature designed to protect the active ingredient until it reaches the intestine. Additionally, a sterile Solution for intravenous (IV) infusion is utilized in clinical settings, typically reserved for situations where the oral route is compromised or rapid systemic delivery is required.

What side effects are possible with Unizink?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics for zinc preparations, consistent with regulatory guidelines for an essential trace element supplement.

Gastrointestinal Adverse Reactions

The most commonly reported adverse effects involve the digestive system. Regulatory classifications derived from official documents indicate that vomiting may be Very Common (ge 10%), particularly in children and often shortly after the first dose. Other effects categorized as Common or of Unknown Frequency include nausea, diarrhea, abdominal pain, dyspepsia, and general gastric irritation.

Serious Systemic Safety Concerns

Official labeling documents a critical risk associated with the long-term use of high-dose zinc preparations: the development of secondary copper deficiency. This can lead to serious Blood and Lymphatic System Disorders, including anemia and neutropenia (a reduction in a type of white blood cell). Less frequently reported but documented serious adverse reactions include gastric ulcer or perforation associated with long-term zinc acetate use.

Safety Restrictions and Population Considerations

Periodic monitoring of hematological and biochemical parameters (such as blood counts and liver/kidney function) is required for patients undergoing long-term zinc treatment. Caution is explicitly warranted for older adults and individuals with renal impairment due to the higher potential for decreased organ function and increased accumulation risks. Additionally, zinc preparations are generally contraindicated in patients with a known hypersensitivity to the active substance or any excipients.

Overdose and Emergency Response

This section outlines the officially documented clinical and emergency information concerning an overdose of zinc preparations, as specified in regulatory labeling. Acute overdose may manifest with severe gastrointestinal signs, including vomiting, watery diarrhea, abdominal pain, and in serious instances, GI hemorrhage. Documented systemic manifestations include blurred vision, tachycardia, and marked hypothermia. The most severe outcomes listed in official sources involve Life-Threatening Cardiopulmonary and Organ Injury, such as pulmonary edema, acute kidney injury, and liver necrosis, with specific mention of fatality risk.

Regulatory authorities mandate that individuals seek immediate medical attention and contact the Poison Help hotline when an overdose is suspected. The immediate procedural response is supportive, focusing on the management of severe symptoms and the potential for fluid loss. Management measures officially described include the administration of intravenous fluids, antiemetics, and the use of chelation therapy for severe systemic toxicity, underscoring that no single specific antidote is listed. Prolonged intake of excessive zinc may also lead to chronic toxicity, primarily documented as zinc-induced copper deficiency, which can result in specific blood abnormalities like neutropenia and anemia. Official requirements for monitoring include vital signs and laboratory testing of serum zinc and copper levels, particularly in cases of impaired kidney function.

Therapeutic Uses of Unizink

What Unizink Treats: Main Uses and Benefits

The core therapeutic application of Unizink (Zinc Aspartate) is commonly used for the essential correction of zinc deficiency, which may be part of symptomatic management and support across several domains of physiological function. Zinc is a trace element essential for multiple physiological functions. It is considered relevant in clinical situations where symptomatic distress is commonly linked to this essential micronutrient imbalance.

Unizink is applied across domains where patients experience symptoms related to systemic imbalance, such as those linked to impaired immune function, slow-healing chronic wounds, dermatitis, and sensory impairments like altered taste or smell. It supports the patient during difficult episodes by providing the essential element needed to address these systemic symptoms.

“It is a foundational treatment, relevant in contexts marked by increased systemic burden due to essential micronutrient depletion.”

Quick Fact: Relief for Systemic Imbalance

Unizink may assist with maintaining functional stability when conditions, such as malabsorption syndromes or chronic liver disease, produce symptoms that create noticeable physiological strain related to a persistent zinc deficit. It contributes to improved comfort during these periods by addressing the symptoms related to nutritional imbalance.

Regulatory References

  1. NIH MedlinePlus overview on Zinc

Eligibility and Restrictions for Use

Who Can and Cannot Use Unizink?

Eligibility for Unizink (Zinc Aspartate) is strictly determined by official regulatory labeling, focusing on certain health conditions and age groups.


Absolute Contraindications and Exclusions

Use of Unizink is formally contraindicated in specific patient populations:

  • Impaired Kidney Function: Patients with renal failure or significantly impaired kidney function must not use this medicine due to the high risk of elemental zinc accumulation and toxicity.
  • Hypersensitivity: Individuals with a known hypersensitivity to the active ingredient, Zinc Aspartate, or to any of the excipients in the specific formulation are ineligible.

Population Eligibility and Restrictions

Population Category Eligibility Status (Regulatory)
Adults, Adolescents, Children (ge 1 year) Use is established and allowed for treating confirmed zinc deficiency.
Infants (Under 1 Year) Use of the oral preparation is not recommended by regulatory bodies.
Pregnancy and Breastfeeding Use is conditional and requires mandatory prior consultation with a healthcare professional.
Core Prerequisite Eligibility is restricted to a confirmed zinc deficiency that cannot be corrected through diet alone.

Eligibility in all cases is restricted to those for whom a zinc deficit is officially diagnosed.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Unizink (Zinc Aspartate) is defined by its ability to interfere with the gastrointestinal absorption of other substances. This primarily occurs through chelation in the gut and competitive mineral uptake. Regulatory documents classify these as clinically significant interactions that necessitate administration modification through timing rules.

Medicines Requiring Timing Separation Co-administration with this preparation may lead to reduced systemic exposure of both medicines, requiring a minimum separation interval of three to six hours. This applies to several categories of medicinal products:

  • Tetracycline Antibiotics: Includes agents such as tetracycline and oxytetracycline.
  • Quinolone Antibiotics: Includes fluoroquinolones like ciprofloxacin and levofloxacin.
  • Chelating Agents: Substances such as Penicillamine and Trientine.

Other Officially Documented Interactions

  • Iron Supplements: Zinc absorption may be reduced by oral Iron, and the zinc preparation may likewise reduce the absorption of oral iron due to competitive uptake; a separation of at least two hours is required.
  • Copper Supplements: Prolonged administration of high-dose zinc may reduce the absorption of copper, leading to a pharmacodynamic mineral imbalance.
  • Dietary Factors: The absorption of the zinc ion is formally documented to be reduced when administered concurrently with high-phytate or high-fiber foods and certain Calcium and Phosphorus containing compounds.

Interaction-Context Constraint No combination is strictly prohibited (contraindicated); rather, all documented interactions are managed by mandatory administration timing rules to prevent significant reduction in the absorption of the interacting agents.

Mechanism of Action

Modulating Receptor- and Enzyme-Mediated Signaling

Unizink (Zinc-aspartate) exerts its action within mechanistic domains involving receptor- or enzyme-mediated signaling pathways. Zinc functions as an essential cofactor for numerous metalloenzymes, including those involved in nucleic acid metabolism and protein synthesis. Its bioavailability allows it to modify early molecular steps within these systems. This engagement with key molecular machinery modulates signaling sequences that regulate cellular reactivity by influencing enzyme conformation and activity.


Influencing Cellular Processes and Feedback Regulation

The mechanism involves the regulation of specific intracellular processes relevant to maintaining cellular ion homeostasis and modulating redox state. By altering pathway activity, Unizink influences the systemic effect resulting from increased mediator concentrations. It targets cascades where multiple layers of pathway activation occur, specifically by modulating feedback regulation within those pathways. The resulting mechanistic effect induces a change in pathway kinetics, influencing the final physiological state.

Dosage and Administration Information

Administration Guidelines for Unizink

These guidelines detail the method for administering Unizink (zinc aspartate).

Route and Dosing Schedule

The medicine is taken via the oral route. The prescribed dose and frequency depend on the patient's age or body weight, as defined in the product information. For example, the typical dosing for adolescents and adults is one tablet daily (equivalent to 10 mg elemental zinc).

Age/Weight Group Standard Dosing (Example)
Adults & Children over 12 years 1 tablet daily (or as directed)
Children 1–10 years 1 tablet daily (or as directed)

Administration Timing and Procedure

The timing of administration is a key procedural condition for this product. Tablets must be swallowed whole with sufficient liquid; they should not be sucked. For optimal absorption, the tablets are generally taken on an empty stomach, about 30 to 60 minutes before a meal. If a dose is missed, patients should take it as soon as they remember, unless it is almost time for the next scheduled dose, in which case the missed dose is skipped, and the regular schedule is resumed. The dose should not be doubled.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Unizink

Evidence for Use in Correcting Confirmed Zinc Deficiency

Research has explored the evaluation of zinc supplementation in individuals with a confirmed diagnosis of zinc deficiency, whether due to nutritional lack or specific underlying conditions. These studies included diverse populations, such as children, adults, and individuals with rare genetic conditions that affect zinc absorption.

The main focus of these research efforts was to monitor physiological strain or stress, specifically by measuring changes in blood zinc levels, and to observe how symptoms evolved in the observed populations, such as changes in physical signs linked to deficiency. Findings describe patterns related to shifts in these circulating zinc biomarkers following supplementation. This research related to this diagnosed deficiency contributes to the broader evidence landscape.

However, certain aspects remain under investigation. The process for accurately determining a mild or marginal deficiency is challenging because blood zinc levels can be an uncertain indicator of the body’s overall zinc status. Furthermore, while the short-term outcomes related to biomarker changes are well-documented, there is limited information for long-term outcomes characterizing maintenance of status and functional stability beyond extended periods.

Evidence Related to Immune Function and Infection Frequency

Zinc supplementation was studied for its relationship with outcomes related to systemic or functional imbalance, specifically in the context of the immune system. Research has examined this in populations such as older adults with observed low baseline zinc status, and children living in areas where dietary zinc intake is often low. The studies explored short-term symptom changes, primarily by monitoring outcomes describing episodic or acute changes, such as the incidence, severity, and duration of common infections like the cold.

Some trials described patterns observed in the studies where data show patterns related to differences in the reported frequency of infections, particularly in groups with a low pre-study zinc status. However, research highlights changes measured during the study period, and findings were mixed when examining the duration of the common cold, with the outcome often depending on the specific type of zinc product used and when the intervention was started. Overall, the evidence derived from settings with varying symptom burdens indicates heterogeneity in these findings.

Evidence for Chronic Wounds and Dermatological Conditions

Research examined the use of zinc supplementation in conditions where symptoms may vary in intensity, specifically for patients dealing with slow-healing chronic skin ulcers and various forms of dermatitis known to be associated with low zinc status. These research scenarios focused on outcomes related to physical discomfort and functional imbalance, using measurements like the rate of wound closure and changes in the size of the affected area.

Studies conducted during periods of increased symptom activity in individuals with both chronic wounds and confirmed low zinc status have reported differences in the measurements related to the rate of wound closure. Findings describe group patterns most consistently in the context of changes in specific dermatological symptoms directly related to severe, diagnosed zinc deficiency disorders.

Key Studies & References

  1. Zinc and gastrointestinal disease
  2. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc

Frequently Asked Questions (FAQ)

Common questions about Unizink (FAQ)


Q: Can Unizink affect my ability to drive or operate machinery?

A: Official documentation for zinc products generally does not list effects on driving ability or the ability to operate machinery. This suggests no significant impairment is expected from the medication itself. However, it is always recommended to review the specific product information for any known adverse reactions that could potentially affect your attention or coordination.


Q: Is it normal to feel a bit nauseous when first starting Unizink?

A: Yes, gastrointestinal issues are frequently reported with zinc preparations. Adverse effects like nausea and vomiting are very common, particularly in children, and may occur shortly after the first dose. This is a recognized part of the medication’s adverse reaction profile.


Q: Can taking Unizink cause hair loss or changes in hair texture?

A: Hair loss is not typically listed as a direct side effect of Unizink in regulatory adverse reaction sections. However, prolonged use of high-dose zinc can lead to a secondary deficiency of copper. Copper deficiency can, in turn, cause serious blood disorders, but no direct link to hair changes is commonly documented as an adverse drug reaction in regulatory labeling.


Q: Are there any specific foods or drinks that should be avoided while taking Unizink?

A: Regulatory documents note that the absorption of the zinc ion can be reduced when taken with certain dietary factors. This includes high-phytate or high-fiber foods, as well as certain compounds containing calcium and phosphorus. Following the required timing rules, such as taking the medication away from meals, helps minimize potential interference.


Q: Can Unizink impact sleep patterns?

A: Central nervous system (CNS) effects that might interfere with sleep are only listed if they were reported in clinical trials. Unizink is not typically associated with common sleep disturbances. If any effect on sleep patterns were to occur, it would typically be considered rare or of unknown frequency, unless explicitly documented in the product information.


Q: Are there different strengths or formulations of Unizink available?

A: Yes, Unizink is presented in several forms to suit different needs. It is commonly available for oral use as film-coated tablets and enteric-coated tablets. A sterile solution for intravenous (IV) infusion is also utilized in hospital settings when oral administration is not feasible.


Q: Do I need to check my zinc levels before starting Unizink?

A: Official regulatory documents state that the use of Unizink is restricted to individuals with a zinc deficit that has been officially diagnosed. Furthermore, for patients undergoing long-term treatment, periodic monitoring of blood parameters is required.


Q: How long after stopping Unizink do the effects wear off?

A: Pharmacokinetic data describes that ingested zinc is mostly eliminated from the body through the stool. The time it takes for any therapeutic effects to diminish after discontinuing the medication is highly dependent on an individual's baseline zinc status and overall metabolism, and this duration is not quantified in the drug labels.


Q: Is it okay to drink coffee while taking Unizink?

A: Coffee itself is generally not listed as a specific interaction in regulatory documents. However, if coffee is consumed with dairy, the presence of calcium may interfere with zinc absorption. Following the administration timing rules helps to minimize potential interference from dietary factors, including those that might affect absorption.


Q: What is the maximum amount of time Unizink is typically used for a course of treatment?

A: There is no fixed maximum duration listed for Unizink use. However, official warnings highlight that if the medication is taken for a long term, continuous periodic monitoring of blood parameters is required. The monitoring is required due to the risk of developing a serious secondary copper deficiency.


Q: Are the side effects of Unizink generally dose-dependent?

A: While regulatory labeling does not explicitly state that all adverse effects are proportional to the dose, official warnings connect the most serious risks to high dosage and long-term use. The development of secondary copper deficiency and severe gastrointestinal reactions are associated with the use of high-dose zinc preparations, suggesting a relationship between the amount taken and the safety risk.


Q: How is Unizink eliminated from the body?

A: According to pharmacokinetic properties described in regulatory texts, the vast majority of the ingested zinc, approximately 90%, is eliminated from the body through the stool. A smaller amount is eliminated through the urine and perspiration.


Q: Are there specific symptoms that Unizink is known to improve?

A: Unizink is authorized to treat confirmed zinc deficiency. Improvement is observed by how symptoms linked to that underlying deficiency evolve over time. This may include changes in physical signs, the healing rate of chronic wounds, or outcomes related to infection frequency, particularly in individuals who started with a low zinc status.


Q: Does Unizink make you gain or lose weight?

A: Weight change is not listed as a common adverse reaction of the medication itself. However, severe zinc deficiency is often associated with appetite disorders and weight loss. Correcting the underlying deficiency with Unizink may indirectly lead to a stabilization or gain in weight as the patient's nutritional status improves.


Q: What does current research say about Unizink for chronic conditions?

A: Research supports the use of Unizink in chronic conditions where confirmed zinc deficiency plays a role. This includes specific studies on slow-healing chronic skin ulcers, certain forms of dermatitis, and, in groups with low baseline zinc status, the modulation of outcomes related to systemic imbalance and infection frequency.


Q: Can Unizink be taken by someone with a sensitive stomach?

A: The formulation uses Zinc Aspartate, an organic zinc complex that official documents suggest is designed for enhanced gastric tolerance compared to simple inorganic salts. Despite this, users should be aware that gastrointestinal irritation, nausea, and vomiting remain commonly reported side effects across all zinc preparations.


Q: Does Unizink need to be stored in the refrigerator?

A: No, Unizink tablets do not require refrigeration. Official storage guidelines specify that the product must be kept in its original packaging at a temperature up to 25°C, in a dry place, and away from direct sunlight.


Q: Can Unizink be crushed or split if it's a tablet?

A: No, official instructions state that the tablets must be swallowed whole with sufficient liquid and should not be sucked. This requirement is in place to ensure that the medication is absorbed correctly and to protect the active ingredients and the digestive tract.


Q: Is Unizink considered a mineral or a drug?

A: Unizink is classified as an essential trace element supplement, which is a mineral. However, because it is used to treat a diagnosed deficiency and is categorized within the high-level pharmacological class of zinc preparations, it is classified and regulated as a medicinal product for zinc substitution.

How should Unizink be stored and disposed of?

How to Store and Dispose of Unizink

Official regulatory guidelines for Unizink 50 (Zinc Aspartate) define strict conditions to maintain product quality and safety.


Required Storage Conditions

Unizink 50 tablets must be stored at a temperature up to 25°C. The product requires protection from the environment and must be kept in a dry place and out of direct sunlight.

Requirement Official Statement
Temperature Up to 25°C
Packaging Must be stored in the original package
Protection Keep in a dry place; out of direct sunlight
Safety Store out of reach of small children

Disposal

Specific instructions for the disposal of unused or expired Unizink are not consistently provided in the official product labeling. Disposal should follow established guidelines, such as utilizing local medicine take-back programs or general household disposal procedures, to ensure safe and appropriate discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Unizink found in:

A-Z Index: